SHPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SHPH is not a good buy right now for an impatient investor. The stock is selling off hard today (down ~9% regular session and additional weakness pre-market), there are no proprietary buy signals, no news/catalysts to reverse sentiment, and the latest reported quarter still shows deepening losses with essentially no revenue. This setup favors staying on the sidelines rather than buying into weakness.
Price/Trend: SHPH is in a short-term down move (current ~2.04, -9.13% today) and is trading well below the pivot level (2.692), which is technically bearish. The nearest key support is S1 ~1.573 (a realistic downside magnet if selling continues); resistance overhead starts at the pivot (2.692) and then R1 ~3.812. Momentum: MACD histogram is above zero (0.0296) but positively contracting, implying bullish momentum is fading rather than strengthening. RSI(6) ~45.38 is neutral—no oversold reading to suggest an immediate bounce is statistically favored. Moving Averages: Converging MAs typically indicate indecision/transition, but with today’s sharp drop the bias remains downside until price reclaims the pivot zone. Pattern-based expectation: Similar-candlestick analysis implies a slightly negative next-day bias (-0.65%) and modest positive 1-month expectation (+5.56%), but near-term technicals do not support an urgent entry.
Intellectia Proprietary Trading Signals Intellectia Proprietary Trading Signals
No news in the last week (no immediate event-driven catalyst). Pattern-based projection shows a potential positive drift over the next month (+5.56%), suggesting a rebound is possible if selling exhausts near support.
increases the probability of a continuation move toward support (S1 ~1.573). Lack of fresh news/catalysts reduces the odds of an abrupt sentiment reversal. Trading trends show no meaningful hedge fund or insider accumulation signals recently (both neutral).
Latest quarter: 2025/Q3. Revenue remained effectively 0 (0.00% YoY change), while losses worsened: Net Income fell to -2,347,302 (down -37.97% YoY) and EPS dropped to -1.05 (down -97.35% YoY). Overall, the quarter shows no revenue traction and deteriorating earnings power, which weakens the fundamental case for buying dips.
No analyst rating/price target change data provided, so there is no visible Wall Street-driven support (upgrades/target raises) to lean on. Pros: none evidenced from the provided dataset. Cons: absence of coverage or disclosed positive revisions often coincides with limited institutional sponsorship.
